News + Filings Transactions Holdings
All 13F 13D/G Other
|
Flynn James E
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
05/23/2023 |
SC 13D/A
| Flynn James E reports a 4.9% stake in CalciMedica, Inc. |
03/28/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
03/27/2023 |
SC 13D/A
| Flynn James E reports a 24.5% stake in CalciMedica, Inc. |
12/21/2022 |
SC 13D/A
| Flynn James E reports a 11.6% stake in Oncorus, Inc. |
11/23/2022 |
SC 13D/A
| Flynn James E reports a 24.5% stake in Graybug Vision, Inc. |
09/16/2022 |
SC 13D/A
| Flynn James E reports a 42.4% stake in Larimar Therapeutics, Inc. |
07/05/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
04/27/2022 |
SC 13D/A
| Flynn James E reports a 9.4% stake in Acutus Medical, Inc. |
11/19/2021 |
SC 13D/A
| Flynn James E reports a 4.9% stake in DFP Healthcare Acquisitions Corp. |
08/26/2021 |
SC 13D/A
| Flynn James E reports a 9.5% stake in Acutus Medical, Inc. |
07/21/2021 |
SC 13D/A
| Flynn James E reports a 17.2% stake in Acutus Medical, Inc. |
07/13/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
07/02/2021 |
SC 13D/A
| Flynn James E reports a 32.9% stake in Larimar Therapeutics, Inc. |
07/01/2021 |
SC 13D/A
| Flynn James E reports a 36.4% stake in DFP Healthcare Acquisitions Corp. |
06/14/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
05/26/2021 |
SC 13D/A
| Flynn James E reports a 33.5% stake in Larimar Therapeutics, Inc. |
05/21/2021 |
SC 13D/A
| Flynn James E reports a 33.5% stake in Larimar Therapeutics, Inc. |
02/22/2021 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
01/08/2021 |
SC 13D/A
| Flynn James E reports a 0% stake in Protara Therapeutics, Inc. |
11/20/2020 |
SC 13D/A
| Flynn James E reports a 25.2% stake in Graybug Vision, Inc. |
07/01/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
06/25/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
05/26/2020 |
SC 13D/A
| Flynn James E reports a 37.9% stake in AdaptHealth Corp. |
05/05/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
05/01/2020 |
SC 13D/A
| Flynn James E reports a 5% stake in Homology Medicines, Inc. |
04/20/2020 |
SC 13D/A
| Flynn James E reports a 7.1% stake in Homology Medicines, Inc. |
03/30/2020 |
SC 13D/A
| Flynn James E reports a 40.2% stake in AdaptHealth Corp. |
01/31/2020 |
SC 13D/A
| Flynn James E reports a 9.3% stake in Homology Medicines, Inc. |
01/24/2020 |
SC 13D/A
| Flynn James E reports a 42.7% stake in AdaptHealth Corp. |
01/17/2020 |
SC 13D/A
| Flynn James E reports a 7.4% stake in ArTara Therapeutics, Inc. |
12/30/2019 |
SC 13D/A
| Flynn James E reports a 11.9% stake in Homology Medicines, Inc. |
11/15/2019 |
SC 13D/A
| Flynn James E reports a 50.4% stake in AdaptHealth Corp. |
11/13/2019 |
SC 13D/A
| Flynn James E reports a 10% stake in Proteon Therapeutics, Inc. |
11/08/2019 |
SC 13D/A
| Flynn James E reports a 10% stake in Proteon Therapeutics, Inc. |
|
|
|